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included the cost of drugs, needles, hypoglycaemia and serious adverse events. 
The prices of drugs and needles were accounted by Chinese market retail price. 
The costs of hypoglycaemia, serious adverse events and weight loss were 
obtained from published data. All costs were adjusted to 2012 Chinese value 
based on China Consumer Price Index. Results were calculated as the difference 
of total expenditures of Liraglutide versus Insulin Glargine divided by the 
difference of patients achieving target. One-way sensitivity analyses were 
performed. RESULTS: The total cohort cost was CNY 1,658,112 (Liraglutide 
1.8mg), 1,101,812 (Liraglutide 1.2mg), and 881,326 (Insulin Glargine). Number of 
patients successfully achieving the composite endpoint was 40 (Liraglutide 
1.8mg), 32 (Liraglutide 1.2mg), and 15 (Insulin Glargine).Thus incremental cost 
per successfully treated patient was CNY 12,970 and CNY 31,071 for Liraglutide 
1.2mg and 1.8mg versus Insulin Glargine respectively. Sensitivity analyses of the 
safety parameters suggested results were robust. CONCLUSIONS: Liraglutide was 
a cost-effective treatment approach versus Insulin Glargine for treating T2DM in 
a Chinese setting. The incremental costs were less than CNY 37,784 of estimated 
China GDP per capita in 2012.  
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A MARKOV MODEL TO ASSESS THE INCREMENTAL COST EFFECTIVENESS 
RATIO FOR OPTIMAL STATIN UTILIZATION AS COMPARED WITH CURRENT 
USE: AN ANALYSIS OF MEDICAID BENEFICIARIES HAVING TYPE-2  
DIABETES  
Regine M1, Kogut S2 
1University of Rhode Island, Kingston, RI, USA, 2University of RI, Kingston, RI, USA  
OBJECTIVES: To determine the prevalence of HMG-CoA reductase inhibitor 
medication use (i.e. “statin” drugs), assessing both prescribing rates and patent 
adherence to therapy, among a population of older Medicaid beneficiaries having 
type 2 diabetes in Rhode Island. Current prescribing and adherence rates were 
contrasted with an optimal use scenario using a Markov model, considering cost 
and benefit as measured in terms of predicted reductions in the incidence of 
fatal and non-fatal ischemic stroke. METHODS: We simulated expanded statin 
utilization among Rhode Island Medicaid beneficiaries age 65 or older having 
type 2 diabetes, evaluating the cost-effectiveness of increased utilization  
of statin medications. The benefit of statin use was focused on decreased stroke 
risk. Transition probabilities were derived from risk estimates generated  
for stroke, calculated from the General Practice Research Database across 
stratified gender and age groups in a cohort of 24,835 people with type 2 
diabetes. Cost-effectiveness analysis was used to project costs and benefits of 
increased levels of statin utilization contrasted with current levels of statin 
utilization. RESULTS: Premised upon the population's (N = 4,217) actual 
utilization of statin medications, predicted outcomes over a 5-year period 
included 338.53 acute stroke events; 46.69 fatal stroke events; 1,506.17 deaths 
from other causes, with a total 5-year cost of drug therapy estimated to be 
$265,832. Based upon the optimal statin use scenario, predicted outcomes 
included 272.87 acute stroke events; 37.49 fatal stroke events; and 1,508.20 
deaths from other causes, with a 5-year cost of drug therapy estimated to be 
$724,871. The resulting cost per stroke avoided was $6,991, while the cost per 
fatal stroke avoided was $49,858. CONCLUSIONS: From the perspective of the 
Medicaid payer, improving statin drug utilization in this population of older 
Medicaid-enrolled patients having type 2 diabetes is a cost-effective intervention 
for preventing ischemic stroke.  
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EVALUATING SHORT-TERM COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS 
ORAL ANTIDIABETIC DRUGS IN PATIENTS WITH TYPE 2 DIABETES IN A 
CHINESE SETTING  
Shi LW1, HAN S1, Sun F2, LIU F2 
1Peking University, Beijing, China, 2Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, 
China  
OBJECTIVES: To evaluate the cost-effectiveness of Liraglutide 1.2mg once daily 
versus oral antidiabetic drugs (OAD) in patients with type 2 diabetes (T2DM) 
achieving a composite endpoint of HbA1c<7.0%, no weight gain, and no 
hypoglycaemia at week 26 in a Chinese setting. METHODS: This short-term cost-
effectiveness study compared Liraglutide with Rosiglitazone, Glimepiride and 
Sitagliptin respectively. Effectiveness data of patients with T2DM achieving the 
composite endpoint of HbA1c<7.0%, no weight gain, and no hypoglycaemia at 
week 26 were derived from a meta-analysis (Zinman et al. 2012). Safety data 
were obtained from randomized, controlled, phase 3 trials including Liraglutide 
Effect and Action in Diabetes (LEAD) 1, LEAD2 and 1860 trial. Medical costs 
included the cost of drugs, needles, hypoglycaemia and serious adverse events. 
The prices of drugs and needles were accounted by the market retail price 
published by National Development and Reform Commission. The costs of 
hypoglycaemia, serious adverse event and weight loss were obtained from 
published data. All costs were adjusted to 2012 Chinese value based on China 
Consumer Price Index. Results were calculated as the difference of total 
expenditures of liraglutide versus comparators divided by the different number 
of patients achieving the target. One way sensitivity analysis was performed. 
RESULTS: Within 26 weeks, comparing with Rosiglitazone, Glimepiride and 
Sitagliptin, Liraglutide 1.2mg made 26, 24 and 21 additional patients achieve the 
composite endpoint among every 100 patients respectively. The incremental cost 
per successfully treated patient with Liraglutide 1.2mg was CNY 20,145, CNY 
26,899, and CNY 33,561 versus Glimepiride, Rosiglitazone, and Sitagliptin 
respectively. Sensitivity analyses demonstrated robustness of the results. 
CONCLUSIONS: This analysis demonstrated that Liraglutide was cost-effective 
compared to Glimepiride, Rosiglitazone, and Sitagliptin in a Chinese setting. The 
incremental costs were less than CNY 37,784 of estimated China GDP per capita 
in 2012.  
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DETECTION OF TYPE-2 DIABETES IN YOUNG ADOLESCENTS  
Ashok P, Kharche J, Balsubramanian B, Joshi AR 
Bharati Vidyapeeth Deemed University, pune, India  
OBJECTIVES: According to World Health Organisation, type-2 diabetes has 
recently escalated in all age groups and is now being identified in younger and 
younger age groups, including adolescents and children, especially in high-risk 
population. This underscores the need for mass awareness and screening 
programmes to detect diabetes at an early stage and early age cost effectively. 
For this purpose we have planned to use a simplified Indian Diabetes Risk Score 
[IDRS] for prediction of diabetes in young adolescents of Bharati Vidyapeeth 
Deemed University Medical College. METHODS: A total of 261 students of said 
Medical College will be screened using IDRS which includes age, family history of 
diabetes, exercise status and Waist circumference. After scoring them they will 
be categorised into mild, moderate and high risk group. In students who are 
having score more than 50, Random Capillary Blood Glucose (RCBG) were 
assessed with the help of glucometer. RESULTS: We have assessed 261 students 
till now. It was observed that 5% ,55% & 38% students in high, Moderate & Low 
risk group respectively for developing type 2 D.M. Mean abdominal obesity in 
high risk students was 101.95± 5.76 as compared to 79.17 ± 11.08 in moderate and 
low risk students(p<0.0001). Family history of diabetes in either or both parents 
was present in 25% students. 63% students were having sedentary lifestyle. Mean 
RCBG in students having score more than 50 was 97.33 ±9.68 mg/dl. Also, 3 
students were having RCBG >103mg/dl. CONCLUSIONS: This underscores the 
need for further investigations. IDRS is the simplest way to screen large 
population. To prevent and to postpone the risk of type 2 diabetes mellitus, 
health education programme, exercise and diet planning can be recommended 
for these students.Thus this mayprove as a cost effective solution of detection of 
risk of type-2 diabetes mellitus.  
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COST-EFFECTIVENESS ANALYSIS OF USING HYPOGLYCEMIC AGENTS 
(LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN, GLIMEPIRIDE  
AND GLIBENCLAMIDE) WITH METFORMIN IN DIABETES IN  
COLOMBIA  
Romero M1, Marrugo R1, Sanchez O1, Lopez S1, Alvis N2 
1Fundacion Salutia, Bogota, Colombia, 2Hospital Infantil Napoleón Franco Pareja, Cartagena de 
Indias, Colombia  
OBJECTIVES: To Analyze the cost-effectiveness of using oral hypoglycemic 
agents (linagliptin, saxagliptin, sitagliptin, vildagliptin, glimepiride and 
glibenclamide) each associated with metformin, to control type-2 diabetes 
mellitus in patients with inadequate glycemic control, from a third-party’s payer 
perspective. METHODS: A Monte Carlo-type Markov model was used to simulate 
disease natural history. The outcomes of interest were fatal infarct, acute 
myocardial infarction, stroke, nephropathy, moderate or severe hypoglycemia 
and changing of treatment, expressed in years of life (LY). Drug costs were taken 
from market average at prices for 2012 expressed in Colombian pesos. Direct 
medical costs were taken from insurers and individual health benefit records 
(SISMED). A discount rate of 5% was applied both to cost and outcomes. 
RESULTS: As a main outcome the measures of life years (LY) are nearly similar 
for each combined treatment. However linagliptin is barely a most effective 
treatment with 13.71 life years discounted, followed by sitagliptin and 
vildagliptin with 13.70 and 13.60 life years discounted respectively. Similarly, 
linagliptin is the least expensive (COP$69,396,763 discounted annually) while 
saxagliptin and vildagliptin have a cost of COP$71,941,693 and COP$71,713,900 
discounted, respectively. It was found that linagliptin, vildagliptin and sitagliptin 
are nearly similar with respect to life years (LY) and each one is placed below the 
efficient frontier. Among the oral hypoglycemic agents analyzed, only three 
(linagliptin, vildagliptin and sitagliptin) are cost-effectives, being linagliptin the 
most. Glibenclamide is the only technology included in the Colombian health-
care benefits plan and is the least effective and the most expensive one. 
CONCLUSIONS: Linagliptin, sitagliptin and vildagliptin each one added to 
metformin is nearly similar with respect to life years (LY) and to cost-effectives. 
Linagliptin appears to be an advisable option due to its lower cost and its fewer 
macro and micro vascular events, for diabetic patients with inadequate glycemic 
control in Colombia.  
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COST-EFFECTIVENESS OF THERAPY CONVERSION FROM HUMAN SOLUBLE 
INSULIN TO INSULIN ASPART IN PATIENTS WITH TYPE-2 DIABETES IN A 
CHINESE SETTING  
Xu ZR1, Ye Q2, Zhang YZ3 
1Diabetes Center & Endocrinology Department, 306th Hospital of PLA, Beijing, China, 2Institute of 
Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands, 
3Novonordisk(China) Pharmaceuticals Co., Ltd., Beijing, China  
OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from 
human soluble insulin (HI) to insulin aspart (IAsp) in patients with type 2 
diabetes mellitus (T2DM) in a Chinese setting. METHODS: A published and 
validated computer simulation model of diabetes (CORE Diabetes Model) was 
used to project long-term (30 years) life expectancy, quality-adjusted life years 
(QALY) and direct medical costs. Baseline cohort characteristics and treatment 
effects were based on Asian subgroup (n=154, including patients from China, 
Bangladesh, India, Pakistan, Indonesia, South Korea, Malaysia, Philippines, 
Singapore and Taiwan) in A1chieve study which is a prospective, multi-center, 
open-label, non-interventional, 24-week observational study. Treatment costs 
were derived from drug retail prices in Chinese market. The diabetes 
management and complication costs were obtained from Chinese published 
data. Projections were made from a societal perspective and an annual 
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discounting rate of 3% was used for both costs and health outcomes simulation. 
One-way sensitivity analysis was performed. RESULTS: Therapy conversion to 
IAsp would result in increased life expectancy by 0.81 years per patient (13.93 vs. 
13.12) and QALY by 1.44 QALYs per patient (9.87 vs. 8.43), due to reduced 
incidences of diabetes-related complications. Treatment and management costs 
of diabetes were increased by CNY (Chinese Yuan) 11,690 (48,850 vs. 37,160) and 
1,982 (39,924 vs. 37,942) respectively. However, the costs of complications, 
including cerebrovascular disease, renal complications, ulcer/amputation/ 
neuropathy, eye complications, and hypoglycemia events, were reduced by CNY 
199,028 (102,590 vs. 301,618), resulting in total direct medical cost saving of CNY 
185,357. Sensitivity analyses demonstrated robustness of the results. 
CONCLUSIONS: Switching from HI to IAsp in T2DM patients in China was 
associated with not only improvement of life expectancy and QALYs, but also 
significant reduction in total direct medical costs. Therapy conversion to IAsp 




SHORT AND LONG-TERM COST-EFFECTIVENESS OF STARTING INSULIN 
DETEMIR IN INSULIN-NAÏVE PEOPLE WITH TYPE-2 DIABETES  
Home PD1, Gálvez GG2, Malek R3, Hammerby E4, Nikolajsen A4, Andersen MFB5, 
Henriksen O5 
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting insulin detemir 
(IDet) ± oral glucose-lowering drugs (OADs) in people with type 2 diabetes (T2D) 
in countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people starting IDet in Algeria (n=473), 
India (n=1,491), Mexico (n=101), Indonesia (n=109), South Korea (n=487) and in 
Malaysia based on people in 4 ASEAN countries (n=456). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and fractions of local 
GDP per capita based on starting IDet. CE was pre-defined as <3*GDP. RESULTS: 
One-year ICERs were Algeria (DZD 617,658; USD 7,758; GDP 1.48), India (INR 
58,454; USD 1,054; GDP 0.71), Mexico (MXN 62,952; USD 4,835; GDP 0.48), 
Indonesia (IDR 22,920,222; USD 2,381; GDP 0.68), South Korea (KRW 4,273,409; 
USD 3,935; GDP 0.18), Malaysia (MYR 17,613; USD 5,758; GDP 1.34). 30-year ICERs 
were: Algeria (DZD 368,200; USD 4,625; GDP 0.88), India (INR 39,214; USD 707, GDP 
0.48), Mexico (MXN -2,887; USD -222; GDP -0.02); Indonesia (IDR 3,995,329; USD 
415; GDP 0.12), South Korea (KRW 15,139; USD 14, GDP 0.00) and Malaysia (MYR 
10,499; USD 3,432; GDP 0.80). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Starting IDet in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings based on a 1 and 30 year time horizon.  
 
PDB47  
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching from biphasic 
human insulin 30 (BHI 30) ± oral glucose-lowering drugs (OADs) to biphasic 
insulin aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in 
countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people switching to BIAsp 30 in Saudi 
Arabia (n=401), India (n=866) and Indonesia and Malaysia based on people in 4 
ASEAN countries (n=175). Data were collected on clinical effectiveness, adverse 
events, and outcomes using the EQ-5D questionnaire. CE analyses used the IMS 
CORE diabetes model with 1 and 30 year time horizons, with country-specific 
costs for complications and therapies and background mortality rates. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost/QALY in local 
currencies, USD and in fractions of local GDP per capita based on switching from 
BHI 30 to BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: One-year ICERs 
were: Saudi Arabia (SAR 12,913; USD 3,443; GDP 0.17), India (INR 36,001; USD 649; 
GDP 0.44), Indonesia (IDR 120,507,714; USD 12,520; GDP 2.92), Malaysia (MYR 
40,321; USD 13,180; GDP 3.08). 30-year ICERs were: Saudi Arabia (SAR 837; USD 
223; 0.03 GDP), India (INR 21,696; USD 391, GDP 0.26), Indonesia (IDR 51,416,633; 
USD 5,342; GDP 1.25), Malaysia (MYR 19,967; USD 5,342; GDP 1.25). Sensitivity 
analyses on the 30 year time horizon showed the findings to be robust. 
CONCLUSIONS: Switching from BHI 30±OADs to BIAsp 30±OADs in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings at 1 and 30 year time horizons. The Malaysian analyses showed 
borderline cost-effectiveness using 1 year time horizon but cost-effectiveness 
assuming 30 year time horizon.  
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SHORT AND LONG-TERM COST-EFFECTIVENESS OF SWITCHING THERAPY 
FROM INSULIN GLARGINE TO BIPHASIC INSULIN ASPART 30 IN PEOPLE WITH 
TYPE-2 DIABETES IN SAUDI ARABIA AND INDIA  
Home PD1, Soewondo P2, Shafie AA3, AlRaddady K4, Baadbad R5, Hammerby E6, 
Nikolajsen A6, Andersen MFB7, Henriksen O7 
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching therapy from 
insulin glargine (IGlar) ± oral glucose-lowering drugs (OADs) to biphasic insulin 
aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in Saudi Arabia 
and India based on observational data gathered in routine clinical practice. 
METHODS: The A1chieve® study assessed safety and outcomes over 24 weeks in 
66,726 people with T2D starting insulin analog therapy. Most participants (96%) 
stated better glycemic control as reason to switch therapy, 31% also stated 
problems with hypoglycemia as reason of switch. The CE analyses included 
people switching to BIAsp 30 in Saudi Arabia based on people in 7 Gulf countries 
(n=103) and in India (n=191). Data were collected on clinical effectiveness, 
adverse events, and patient reported outcomes using the EQ-5D questionnaire. 
CE analyses used the IMS CORE diabetes model with 1 and 30-year time horizons, 
with country-specific costs for complications and therapies and country-specific 
background mortality rates. Incremental cost-effectiveness ratios (ICERs) are 
expressed as cost/QALY in local currencies, USD and in fractions of local GDP per 
capita based on switching from IGlar to BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: For both a 1 and 30 year time horizons the switch was found to be less 
costly and have better outcomes. 1-year ICERs were: Saudi Arabia (SAR -8,958; 
USD -2,388; GDP -0.12) and India (INR -60,194; USD -1,086; GDP -0.73). 30-year 
ICERs were: Saudi Arabia (SAR -14,242; USD -3,798; GDP -0.19) and India (INR  
-55,914; USD -1,008; GDP -0.68). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Switching therapy from IGlar 
to BIAsp 30 in T2D as performed in the A1chieve® study was found to be 
dominant across both country settings based on a 1 and 30 year time horizon.  
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Home PD1, Soewondo P2, Hussein Z3, Shafie AA4, AlRaddady K5, Baadbad R6,  
Hammerby E7, Nikolajsen A7, Andersen MFB8, Henriksen O8 
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting biphasic insulin 
aspart 30 (BIAsp 30) therapy ± oral glucose-lowering drugs (OADs) in people with 
type 2 diabetes (T2D) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. METHODS: The 
A1chieve®study assessed safety and outcomes over 24 weeks in 66,726 people 
with T2D starting insulin analog therapy. The CE analyses included people 
starting BIAsp 30 in Saudi Arabia (n=901), India (n=7,546), Indonesia (n=153), in 
Malaysia based on people in 4 ASEAN countries (n=430) and in Algeria based on 
people in 3 countries in North-West Africa (n=279). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and in fractions of 
local GDP per capita based on starting BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: 1-year ICERs were: Saudi Arabia (SAR 10,741; USD 2,864; GDP 0.14), 
India (INR 35,182; USD 635; GDP 0.43), Indonesia (IDR 40,487,477; USD 4,207; GDP 
1.2), Malaysia (MYR 13,061; USD 4,270; GDP 1.00), Algeria (DZD 246,422; USD 3,095, 
GDP 0.73). 30-year ICERs were: Saudi Arabia (SAR -3,004; USD -801; GDP -0.04), 
India (INR 20,516; USD 370; GDP 0.25), Indonesia (IDR 15,710,332; USD 1,632; GDP 
0.47), Malaysia (MYR 8,038; USD 2,627; GDP 0.61), Algeria (DZD 155,659; USD 1,955; 
GDP 0.46). Sensitivity analyses on the 30 year time horizon showed the findings 
to be robust. CONCLUSIONS: Starting BIAsp 30 in T2D as performed in the 
A1chieve® study was found to be cost-effective across all country settings based 
on a 1 and 30 year time horizon.  
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COST-EFFECTIVENESS OF SWITCHING TO INSULIN ASPART FROM HUMAN 
SOLUBLE INSULIN IN CHINESE PATIENTS WITH TYPE-2 DIABETES ON A 
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Ji QH1, Ye Q2, Zhang YZ3 
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OBJECTIVES: To evaluate long-term health economic outcomes of switching 
from human soluble insulin (HI) to insulin aspart (IAsp) on a basal-bolus regimen 
in type 2 diabetes mellitus (T2DM) patients in a Chinese setting. METHODS: The 
previously published and validated IMS Core Diabetes Model was used to project 
long-term life expectancy, quality-adjusted life years (QALY) and total direct 
medical costs. Baseline patient characteristics and treatment effects were based 
on Asian subgroup (n=185, countries including China, Bangladesh, India, 
Pakistan, Indonesia, South Korea, Malaysia, Philippines, Singapore and Taiwan) 
in A1chieve study which is a prospective, multi-centre, open-label, non-
